Compare
Mimedx Group, Inc. vs Accuray Inc vs Artivion, Inc. vs Glaukos Corp
| Latest fiscal year | Mimedx Group, Inc. MDXG | Accuray Inc ARAY | Artivion, Inc. AORT | Glaukos Corp GKOS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $418.63M | $401.95M | $441.33M | $507.44M |
| Revenue growth (YoY) | +20.0% | -12.3% | +13.6% | +32.3% |
| Gross margin | 82.6% | 27.7% | 64.4% | 55.7% |
| Operating margin | 15.3% | -6.6% | 7.6% | -39.3% |
| Net margin | 11.6% | -12.2% | 2.2% | -37.0% |
| Net income | $48.58M | -$49.19M | $9.77M | -$187.69M |
| EPS (Diluted) | $0.32 | n/a | $0.21 | -$3.28 |
| Operating cash flow | $74.00M | -$6.98M | $39.88M | -$14.79M |
| Free cash flow | n/a | -$12.84M | $839.0K | -$22.45M |
| Cash & equivalents | $166.12M | $40.62M | $64.91M | $90.81M |
| Total assets | $342.65M | $443.68M | $884.80M | $893.49M |
| Total liabilities | $86.11M | $401.98M | $436.56M | $237.33M |
| Shareholders' equity | $256.55M | $41.70M | $448.23M | $656.15M |
| Return on year-end equity | 18.9% | -118.0% | 2.2% | -28.6% |
| Shares outstanding | 148.09M | 119.43M | n/a | 57.51M |
Revenue, most recent five fiscal years
| Fiscal year | Mimedx Group, Inc. | Accuray Inc | Artivion, Inc. | Glaukos Corp |
|---|---|---|---|---|
| Latest | $418.63M Ended 2025-12-31 | $401.95M Ended 2026-06-30 | $441.33M Ended 2025-12-31 | $507.44M Ended 2025-12-31 |
| 1 year earlier | $348.88M Ended 2024-12-31 | $458.50M Ended 2025-06-30 | $388.54M Ended 2024-12-31 | $383.48M Ended 2024-12-31 |
| 2 years earlier | $321.48M Ended 2023-12-31 | $446.55M Ended 2024-06-30 | $354.00M Ended 2023-12-31 | $314.71M Ended 2023-12-31 |
| 3 years earlier | $267.84M Ended 2022-12-31 | $447.61M Ended 2023-06-30 | $313.79M Ended 2022-12-31 | $282.86M Ended 2022-12-31 |
| 4 years earlier | $242.02M Ended 2021-12-31 | $429.91M Ended 2022-06-30 | $298.84M Ended 2021-12-31 | $294.01M Ended 2021-12-31 |